Why miss anymore potential runners?
 Recently>>>

ACNNF   alerted .627 high of $1.75  1 week
PRED      alerted .95 high of $3.87  4 weeks
JBCT       alerted  $2.66 high of $12.39
SGMD     alerted .068 high .43
VTPK      alerted $1.28  high $6.99
INTV       alerted .125 high of $ 6.74
CSSI        alerted .06 hit .58
ADAC      alerted .05 hit .18    one day
EPAZ       alerted.022 hit .52   two days
MKSEF   alerted.12 hit .20
BLGI       alerted.127 hit 77
GHHC     alerted .51  hit $1.98
NXGH     alerted .025 hit .07     two days
PVCT       alerted .0425 hit .09
FAGI        alerted .037 hit .684   two days
WCTXF   alerted  .09 hit  .157    two days
LTUM      alerted .125 hit .45
PTOP       alerted .0007 hit .066
SHMN     alerted .0002 and hit .0017
KCPC       alerted  .31 and hit $7.22
REFG      alerted  .028 and hit .092
And there were more.
Members get my alerts first… :  )

Have a great day!

Ron


 

 

~ACNNF 1.50… Plenty of ^ side from here imo,
AusCann Logo
Business Description

AusCann is an Australian based company that was incorporated in September 2014 with the
aim of producing and providing high quality, economical and clinically validated cannabis
medicines to patients. It is bringing together leading expertise and operations across all
aspects of the medical cannabis value chain, beginning with cultivation and production,
through to manufacture and distribution of products and has built a strong team of experts
and partners with international connections. Partners includes TSX listed Canopy Growth
Corporations the largest producer of medicinal cannabis globally and DayaCann, the only
licensed medicinal cannabis grower in Chile.

 News…

Auscann Group’s shares surge following green light for medicinal cannabis export

Tas Alks considers expanding medicinal cannabis project for export

Look at their partners… for me, this spells huge ^ side for ACNNF…
Canopy Growth Corporation (WEED.TO)
Toronto – Toronto Delayed Price. Currency in CA $34.00+1.68(+5.20%) At close: January 5 4:47PM EST
Canopy Growth Corporation is a world leading diversified Canadian cannabis company. It operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. AusCann will work with Canopy to leverage its intellectual property, including its medical cannabis strains and products that are currently sold throughout Canada to over 24,000 patients.

OUR CORE BRANDS

Tweed is the most recognized marijuana production brand in the world. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn’t just sell marijuana, it facilitates a conversation about a product we’ve all heard about but haven’t met intimately yet. It is approachable and friendly, yet reliable and trusted. As marijuana laws liberalize around the world, Tweed will expand its leading Canadian position around the globe.

Spectrum Cannabis is Canopy Growth’s international medical brand, serving as the Company’s healthcare professional and patient-facing identity in medical markets in Canada and around the world. Spectrum Cannabis is focused on the simplification of healthcare interactions, stakeholder outreach, and patient education, applying a colour-coded Spectrum to classify cannabis that tens of thousands of Canadians rely on each day. With a presence in multiple jurisdictions across several continents, our industry-leading expertise developed in Canada is now available around the world through the Spectrum Cannabis brand.

Bedrocan is the epitome of medical-grade cannabis. Bedrocan BV pioneered medical cannabis in Holland through decades of selection and refinement, leading to standardized, whole bud cannabis strains that patients can rely on. Bedrocan Canada supplies the same standardized strains to the Canadian market through exclusive licensing rights to the American continents, an arrangement it will also enjoy for all future genetic advancements. Due to its consistency over time, Bedrocan’s strains have been used in clinical research in seven European countries. That commitment to research didn’t stay on the east side of the Atlantic – Bedrocan Canada recently launched one of the largest clinical cannabis studies in the world, the EQUAL Study, to evaluate quality of life before and after medical cannabis use.